Journal
JOURNAL OF LEUKOCYTE BIOLOGY
Volume 112, Issue 3, Pages 547-556Publisher
OXFORD UNIV PRESS
DOI: 10.1002/JLB.6A1021-535R
Keywords
cellular immunity; cytokine; humoral immunity; immunogenicity; neutralizing Ab
Categories
Funding
- National Natural Science Foundation of China [31770996]
- Youth Program of National Natural Science Foundation of China [31901062]
- Scientific research planning project of the 13th 5-year plan of Jilin Provincial Department of Education [JJKH20200172KJ]
Ask authors/readers for more resources
The use of recombinant trimeric hemagglutinin (HA) as an antigen in a DNA vaccine shows promise as a competitive candidate vaccine against influenza viruses. It elicits significant immune responses and provides protection against lethal infection.
Influenza viruses continue to threaten public health, and currently available vaccines provide insufficient immunity against seasonal and pandemic influenza. The use of recombinant trimeric hemagglutinin (HA) as an Ag provides an attractive alternative to current influenza vaccines. Aiming to develop an effective vaccine with rapid production, robust immunogenicity, and high protective efficiency, a DNA vaccine was designed by fusing influenza virus HA with self-assembled ferritin nanoparticles, denoted as HA-F. This candidate vaccine was prepared and purified in a 293-6E cell eukaryotic expression system. After BALB/c mice were immunized with 100 mu g of HA-F DNA 3 times, HA-F elicited significant HA-specific humoral immunity and T cell immune responses. The HA-F DNA vaccine also conferred protection in mice against a lethal infection of homologous A/17/California/2009/38 (H1N1) virus. These results suggest that the HA-F DNA vaccine is a competitive vaccine candidate and presents a promising vaccination approach against influenza viruses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available